Latest Ratios: P/E Ratio -15.4x · EV/EBITDA N/A · ROE -39.8%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.8B | $1.6B | $795M | $591M | $318M | $583M | — | — |
| Enterprise Value | $1.8B | $1.5B | $710M | $540M | $70M | $282M | — | — |
| P/E Ratio → | -15.35 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 7.10 | 6.05 | 2.32 | 2.90 | 1.23 | 1.93 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -39.8% | -39.8% | -31.6% | -29.9% | -19.8% | -18.3% | — | — |
| ROA | -37.1% | -37.1% | -29.3% | -28.1% | -19.3% | -16.3% | -112.6% | -768.6% |
| ROIC | -44.8% | -44.8% | -38.1% | -74.0% | -886.0% | — | — | — |
| ROCE | -43.3% | -43.3% | -37.2% | -33.9% | -20.9% | -16.6% | -195.2% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.03 | 0.01 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.28 | -0.25 | -0.25 | -0.96 | -1.00 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -9335.00 | -3122.00 |
Net cash position: cash ($77M) exceeds total debt ($6M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.67 | 14.67 | 23.81 | 13.80 | 45.13 | 84.09 | 8.22 | 0.02 |
| Quick Ratio | 14.67 | 14.67 | 23.81 | 13.80 | 45.13 | 84.09 | 8.22 | 0.02 |
| Cash Ratio | 14.15 | 14.15 | 23.40 | 13.27 | 44.06 | 83.57 | 8.19 | 0.02 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $60M | $57M | $43M | $42M | $41M | $43M | $43M |
Clinical Trial Execution Risk
Based on reported figures, TYRA trades at a price-to-book ratio of 7.33, which suggests that investors are pricing in significant intangible value from the SNAP platform rather than the company's current tangible asset base, which remains minimal as of the most recent quarterly filing.
The elevated P/B multiple relative to historical norms indicates that the market is assigning a high probability of success to the TYRA-300 clinical program. Investors should monitor whether this valuation premium holds as the company transitions from a discovery-focused entity to a clinical-stage firm, as any delay in data readouts may lead to a sharp contraction in these multiples.
As reported in financial statements, TYRA's ROIC has remained consistently negative, deteriorating to -12.7% in 2026Q1, which reflects the structural reality of a clinical-stage biotech that consumes capital to fund R&D without generating any offsetting operational returns or revenue streams.
The negative ROIC trend is an expected outcome for a company in the pre-commercial phase, yet it highlights the extreme reliance on external equity financing to sustain operations. This trend warrants further investigation into whether the SNAP platform can eventually achieve the efficiency gains necessary to reverse these negative returns once clinical milestones are reached.
According to recent SEC filings, TYRA's current ratio has experienced a significant contraction from 44.83 in 2024Q1 to 20.49 in 2026Q1, signaling that the company's cash reserves are being depleted at an accelerating rate to support the SURF301 clinical trial and broader pipeline development.
While a current ratio of 20.49 remains high by general industrial standards, it is a misleading metric for a pre-revenue biotech that lacks recurring cash inflows. The rapid decline in this ratio suggests that the company's liquidity runway is narrowing, necessitating a potential return to capital markets for further dilution.
Based on the company's current developmental stage, the use of P/E ratios is fundamentally misapplied, as the reported negative earnings of -15.86 TTM obscure the reality that TYRA is a capital-burning platform play rather than a mature business with stable, predictable profit margins.
Investors should instead focus on enterprise value relative to clinical milestones or cash runway metrics, as traditional earnings-based valuation fails to capture the optionality inherent in the SNAP platform. Relying on P/E ratios in this context may lead to erroneous conclusions regarding the company's true intrinsic value and its long-term viability.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TYRA stock.
Tyra Biosciences, Inc.'s current P/E ratio is -15.4x. This places it at the 50th percentile of its historical range.
Tyra Biosciences, Inc.'s return on equity (ROE) is -39.8%. The historical average is -27.9%.
Based on historical data, Tyra Biosciences, Inc. is trading at a P/E of -15.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.